Download 3D...the future for cells

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Cytokinesis wikipedia , lookup

Cell growth wikipedia , lookup

Extracellular matrix wikipedia , lookup

Mitosis wikipedia , lookup

Cellular differentiation wikipedia , lookup

Cell encapsulation wikipedia , lookup

List of types of proteins wikipedia , lookup

Cell culture wikipedia , lookup

Tissue engineering wikipedia , lookup

Amitosis wikipedia , lookup

Organ-on-a-chip wikipedia , lookup

Transcript
3D...the future for cells
LGC scientists, through collaboration with
Reinnervate, a spin-out from Durham University,
are growing cells in a novel three dimensional (3D)
cell culture technology to imitate the more natural
structure of the liver and improve in vitro screening
of potentially toxic compounds.
Image courtesy of Reinnervate
The Requirement
Drug discovery is an expensive and risky business; the
overall attrition rate for developing a drug is calculated
to be 10,000:1, with 30% of new drug candidates
halted due to unforeseen toxicity profiles. Since the
liver is the major site for compound toxicity, due to its
role in drug metabolism and detoxification, it is critical
to predict potential liver toxicity accurately before the
clinical trial stage. At present, animal testing offers the
best means to achieve this. However animal testing
is both expensive and raises ethical issues. In vitro
assays are invariably faster and cheaper than animal
studies, but with them come high levels of experimental
variability. This is acknowledged by UK and European
associations who have recognised the need to increase
the reliability of in vitro predictive toxicology methods.
The Solution
Normal cell culture practice involves growing cells on a
flat surface (2D), an environment that is very different to
the tissues from which they are derived. Therefore, the
challenge to increasing in vitro reliability is mimicking, in
the laboratory, the conditions a cell would experience in
the human body. Reinnervate’s Alvetex™, a unique 3D
scaffold manufactured from porous polystyrene, goes
some way to achieving this by providing a more ‘tissue
like’ environment which allows cells to communicate
and signal to one another, as they would within a
normal tissue.
Implementation
By developing methods to measure the behaviour
of liver cells in this 3D system, LGC has been able
to demonstrate, compared to standard 2D systems,
significantly higher expression of key liver enzymes,
such as Cytochrome P450, involved in drug metabolism.
This in turn has led to improved responses of the cells
to known cytotoxic compounds.
By developing these new measurement techniques
for predictive toxicology, LGC has helped to
demonstrate the significant improvements offered
by Reinnervate’s technology.
Impact
Reinnervate’s Chief Scientific Officer Prof. Stefan
Przyborski says “Collaborating with LGC has given
us access to expertise and equipment that have been
invaluable in helping us achieve results that extend the
application range of our technology. This project has
helped us secure further funding and our product is
now being prepared for commercial release due later
this year”.
LGC is the UK’s designated National Measurement
Institute (NMI) for chemical and bioanalytical
measurement. As such, part of LGC’s role is to support
innovation in industry by developing measurement
solutions that facilitate the translation of new products
and processes into the market place. By independently
demonstrating the value of this novel approach, LGC is
helping to establish improved toxicology screens and to
engender greater industry and regulatory confidence in
such measurements.
Damian Marshall, LGC’s Principal Scientist for cell
biology says “Collaboration is vital to our role as an NMI
enabling us to support companies driving innovation
in the UK. This project has given us the opportunity to
develop techniques which can be used to overcome the
limitations posed by in vitro systems as well as enabling
us to work closely with UK companies developing novel
platform technologies”.
The work described in this case study was funded by
the UK National Measurement System.
For further information, contact:
LGC, Queens Road, Teddington,
Middlesex TW11 0LY, UK
Tel: +44 20 8943 7000
Fax: +44 20 8943 2767
Email: [email protected]
Web: www.lgc.co.uk
NMS Helpdesk
Tel: +44 20 8943 7393
The National Measurement System delivers world-class measurement
for science and technology through these organisations
Email: [email protected]
Web:
www.nmschembio.org.uk
No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any retrieval system,
without the written permission of the copyright holder. © LGC Limited, 2010. All rights reserved. 2490/TK/0610